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Abstract
One of the most promising ways to find drug candidates in drug design is to study the
interactions between target biomolecules and drug candidates accurately. Although ex-
perimental screening methodologies keep improving, it is still costly and time-consuming
to experimentally screen large numbers of potential compounds suitable to a target pro-
tein. On the other hand, computational screening technologies are an alternative method
that can alleviate these challenges. However, these fast computational methods have
lower accuracy than experimental approaches due to the approximations needed to make
them computationally feasible. Hence, an efficient and accurate computational screening
method for large numbers of potential compounds is in urgent need. For this reason, our
group has recently developed a fragment-based quantum chemistry method called XS-
APT (extended symmetry-adapted perturbation theory) to decompose the binding region
(supersystem) between biomolecule and drug into biomolecular subsystems (fragments)
in order to greatly reduce the computational cost without sacrificing accuracy. The main
attractive feature of the XSAPT method is its ability to capture many-body polarization
effects (important for systems with many fragments) which are omitted in traditional
computational screening functions in drug design. Furthermore, the XSAPT interaction
energy can be decomposed into physically meaningful energy components, and we can
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explore how chemical modification of a potential drug molecule may change its binding
affinity by studying the interplay of various energy components. From a computational
point of view, XSAPT is “embarrassingly parallelizable”, consisting of independent tasks
that can be distributed across processors to reduce the scaling to only linear with respect
to the number of fragments as opposed to the typical quantum mechanical methods which
are at least cubic scaling with respect to the total system size. This fast theoretical
method gives accurate binding energies for a variety of challenging non-covalent com-
plexes, and these impressive results indicate that XSAPT is suitable for different binding
environments. For example, XSAPT predicts a qualitatively-correct binding trend for
a series of ionic-organic complexes as compared to experiment. Thus, XSAPT provides
a route to understanding and controlling the ion-macromolecular binding property by
modifying the structure of the macromolecule (a protein for example). The target of
our XSAPT method is to predict accurate interactions between biomolecules and drug
candidates. XSAPT has been employed in studying the interactions between an anti-
cancer drug and DNA, and this binding complex consists of 157 atoms. A benchmark
binding energy of −33.6 ± 0.9 kcal/mol is available from quantum Monte Carlo (QMC)
calculations. Our XSAPT method yields a binding energy of −33.4 kcal/mol, within
the statistical error bars of the QMC benchmark. Hence, accurate binding energies be-
tween DNA and drug molecules can be achieved by our XSAPT method. In summary,
we demonstrated that XSAPT not only reduces the computational cost but also affords
chemically-accurate interaction energies between molecules. These characteristics make
XSAPT a promising method for use in fragment-based drug design to pre-screen large
numbers of potential drug molecules.
Introduction
Pharmaceuticals are important to the quality of human life because they prevent and
treat many diseases. In the drug design process, a compound is specifically designed
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to interact with a specific biological target. The target might be an underexpressed or
overexpressed molecule in the human body that causes disease, or is a biomolecule such
as an enzyme originating from a disease-causing microorganism. For example, a specific
drug molecule interacts with cholesterol to stop its absorption into the body or another
drug might bind with an influenza protein to prevent the influenza virus from infecting
new cells. In short, the search for compounds to effectively interact with these targets is
the central step in drug design.
The most common way to develop a new drug is to screen a molecular library that
includes large numbers of chemical compounds, and those compounds that can interact
with targets receive further attention as potential drug candidates. This trial-and-error
process can take many years and enormous amounts of money. Furthermore, the drug
may not be effective enough or safe enough for human use at the end of the development
period. Hence, a new and efficient method for drug development is demanded. Although
some new experimental screening methods have been proposed recently, these methods
still have many disadvantages, such as expensive instruments, the requirement of high
sample concentration, and the difficulty of screening large numbers of compounds simul-
taneously.1 Due to the rapid development of high-performance computers, computational
screening technologies are alternative methods to design drug molecules. However, the
binding energies predicted by these fast computational methods have lower accuracy than
experimental approaches, because approximations have to be used to make them compu-
tationally feasible. Often, empirical scoring functions have only a loose connection to the
real physics of intermolecular interactions are employed.2,3 Hence, an efficient and also
accurate computational screening method for large numbers of potential compounds is
badly needed in the field of drug design.
It is essential to calculate interactions between molecules in the process of drug design
by using accurate quantum mechanical (QM) methods which are more accurate than
the traditionally empirical scoring functions. However, the computational cost of QM
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methods that exhibit benchmark or “chemical” accuracy (errors . 1 kcal/mol), such as
CCSD(T), scales as O(N7s ) where Ns measures the size of whole system. In other words,
the computational cost increases 128 times when the system size doubles. The high
computational cost limits its applicability to molecules with less than 30 atoms, which is
not sufficient for computational drug design.
(a) (b)
Figure 1: (a) Structure of the protease inhibitor indinavir bound to HIV protease, as
obtained from PDB crystal structure 1HSG.4 (b) An enlarged view of the binding pocket,
consisting of indinavir (opaque ball-and-stick model) along with 16 amino acids and 2
crystallographic waters (translucent tubular model). [Panel (b) is reproduced from Ucisik
et al.5; copyright 2011 American Institute of Physics.]
Consider the human immunodeficiency virus (HIV) protease + drug inhibitor system
that is shown in Fig. 1(a). Even a representative model system (binding pocket of HIV
protease + drug inhibitor), as shown in Fig. 1(b), contains 323 atoms including the drug
indinavir (opaque ball-and-stick model) along with 16 amino acids and 2 crystallographic
waters (translucent tubular model) which makes traditionally accurate QM methods are
intractable. This work is aimed to build a rapid and accurate QM approach for calculating
interactions between molecules to be applied to drug design.
Methods
Fragment-based quantum chemistry methods offer a way to surmount this predicament
and rely on decomposing the large supersystem (the system including all fragments)
into subsystems (fragments) to greatly reduce the computational cost.6–8 Our group has
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developed a fragment-based method called XSAPT6,9–14 in an attempt to achieve chemical
accuracy for interactions, yet remain affordable enough to be applied to systems such as
the one in Fig. 1(b).
number of    -stacked adenines 
Figure 2: Timings for XSAPT(KS) and supersystem DFT calculations for π-stacked
(adenine)n systems. All calculations use the LRC-ωPBE functional and the hpTZVPP
basis set.
I lead off with data illustrating the efficiency of the XSAPT method, as shown in Fig-
ure 2, which plots timings for XSAPT(KS)+D (a modified version of XSAPT). Plotted
is the time required for a single-point energy calculation in (adenine)n strands of increas-
ing length (adenine is a DNA nucleobase). The supersystem DFT method is one of the
most economical QM methods, and the timing results of this method are also shown
in Figure 2 for comparison. Serial timings represent the total time required using one
processor, and the scaling of XSAPT(KS)+D is O(n2) where n is the number of adenine
molecules. Parallel timings represent the actual elapsed time required when the calcula-
tion is simultaneously run on n(n− 1)/2 processors for n adenine molecules. XSAPT is
“embarrassingly parallelizable”, consisting of independent tasks that can be distributed
across processors to reduce the scaling to O(n). Even in serial, XSAPT(KS)+D is just
as efficient as supersystem DFT for (adenine)2, and is substantially more efficient for
larger systems. In parallel, the wall time required for an XSAPT(KS)+D calculation on
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(adenine)10 is only about twice as large as that required for (adenine)2. Moreover, the
XSAPT method is not only efficient as indicated in Figure 2, but also accurate as pointed
out below.
Our XSAPT method is based on the combination of two fragmentation methods, an
explicit polarization method (XPol) and symmetry-adapted perturbation theory (SAPT).
This approach starts from the XPol method, and the primary function of this method is
to capture many-body polarization effects (important for systems with many fragments)
which are omitted in traditional computational screening functions in drug design. In
a subsequent step, we apply a pairwise-additive form of SAPT to capture the rest of
the interactions missing in the XPol step. However, the single-exchange approximation
(SEA) used in the exchange formulas of SAPT makes SAPT unreliable for use in anionic
systems.13,15 Different levels of SAPT methods have been used to systematically study the
binding energies in different ionic systems, and the rescaled formula for SEA has been
proposed to resolve the problem in exchange formulas used SEA.15,16 Such a rescaled
formula for SEA can also been used in XSAPT. The resulting XSAPT method extends
the traditional two-body SAPT method to many-body systems, and it maintains the
computational cost of a two-body system. Furthermore, the XSAPT interaction energy
can be decomposed into physically meaningful energy components,12
EXSAPTint = Eelectrostatic + Eexchange + Einduction + Edispersion , (1)
and we can study the interplay of various energy components, some of which are attractive
and some repulsive, to explore how chemical modification of a potential drug molecule
may change its binding affinity. Furthermore, we have introduced many different tech-
niques to improve the original XSAPT method:
[1] The use of Kohn-Sham (KS) orbitals for XSAPT, or XSAPT(KS). This incorporates
intramolecular electron correlation beyond mean field theory in a relatively low-cost
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way.10
[2] Long-range corrected (LRC) density functionals are used to obtain correct asymp-
totic behavior of exchange-correlation (XC) potentials in an automated and non-
empirical way, instead of using traditional “splicing” schemes that simply “graft
on” proper asymptotic behavior empirically. The latter approach is potentially
problematic in the context of locating minimum-energy geometries.13
[3] Dispersion (van der Waals) interactions are problematic in XSAPT(KS), so we
replace the dispersion terms in XSAPT(KS) with atom−atom dispersion poten-
tials [XSAPT(KS)+D] that are fit to high-level QM data. Furthermore, I have
reformulated XSAPT in the atomic orbital (AO) basis.17 This formulation avoids
the four-index integral transformation that is required in the original, molecular
orbital version of the method.9,11,14 This has the added benefit of reducing the
scaling of XSAPT(KS) from O(N5f ) to O(N3f ) with respect to the fragment size,
Nf .
10,12,14 Two XSAPT families of methods have also been proposed to achieve
sub-kcal/mol binding accuracy. They are XSAPT+D with dispersion contraction
[XSAPT+D+DC],18 and XSAPT with coupled KS dispersion [XSAPT+CKS].19
Results and Discussion
Figure 3 shows binding energy errors for a variety of methods in a biologically-relevant
dataset which includes a wide distribution of interactions in biochemistry. The XS-
APT(KS) family of methods exhibit reasonably small errors and compete with other
high-level methods that are vastly more expensive. All of the methods that outperform
the XSAPT(KS) family of methods exhibit at least O(N5s ) with respect to the size of
the whole system, whereas XSAPT(KS) methods scale as O(N3f ) with respect to size of
a fragment.
The high specificity of binding of ions to a macromolecule (a protein for example)
is highly important in the life cycle of cell, where ion binding often regulates enzymatic
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error (kcal/mol)
Figure 3: Mean absolute errors for (X)SAPT family of methods and the other super-
molecular methods computed for S66 binding energies with respect to CCSD(T)/CBS
benchmarks.
transformations. Hence, it is important to understand the ion-macromolecule binding
property which provides a route to control the ion binding by modifying the structure of
the macromolecule.
Figure 4 shows binding affinities versus experimental results20 for a series of ionic or-
ganic complexes calculated by XSAPT(KS)+D and also the high-level CCSD(T) method,
which is typically of benchmark quality but exhibits O(N7s ) scaling. The errors in XS-
APT(KS) and CCSD(T) are similar, and they also provide a qualitatively-correct binding
trend for those ionic organic complexes as compared to experiment. Thus, XSAPT(KS)
provides a key to understand the binding feature of ions and macromolecules.
The target of our XSAPT method is to predict accurate interactions between drug
candidates and biomolecules. Here, we consider intercalation of the anti-cancer agent
ellipticine into DNA, which involves insertion between two Watson-Crick CG base pairs,
linked by their respective phosphate sugar puckers as depicted in Fig. 5. The structure
depicted in the figure consists of 157 atoms, and a benchmark binding energy is avail-
able from quantum Monte Carlo (QMC) calculations which yield a binding energy of
−33.6 ± 0.9 kcal/mol.21 One of our family of XSAPT methods, sd-XSAPT(KS)14 with
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Figure 4: Binding affinities in kcal/mol versus experimental results20 for a series of
ionic organic complexes calculated by XSAPT(KS)+D and also the high-level CCSD(T)
method.
a three-body dispersion correction, yields a binding energy of −34.4 kcal/mol, within the
statistical error bars of the QMC benchmark. Thus, the accurate binding energy between
DNA and drug molecule can be achieved. Furthermore, the XSAPT method has also been
applied in molecular and ionic clusters, clathrates, and supramolecular complexes.14,17,20
Conclusion
In summary, we demonstrated that XSAPT not only reduces the computational cost (only
linear scaling with respect to system size) but also affords chemically-accurate interaction
energies between molecules. These characteristics make XSAPT a promising method
for use in fragment-based drug design to pre-screen large numbers of potential drug
molecules. In future work, we will use a low-cost classical molecular dynamics method to
generate a series of reasonable binding positions between drug molecules and the binding
pockets of biomolecules, and build a molecular binding library. Then, XSAPT can be
used to predict the placement and binding energy of the drug biomolecule complexes
in that library and compare the performance of traditional empirical scoring functions.
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Figure 5: Ellipticine molecule intercalated into a GC:GC segment of DNA; binding en-
ergies computed with various methods are shown. XSAPT calculations used three frag-
ments: neutral ellipticine and two single-stranded GC complexes, each with with a −1
charge.
Because XSAPT allows us not only to predict binding energies but also to understand
their physical nature, systematic trends in the errors may emerge that provide clues as
to how to improve empirical scoring functions.
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